The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Biocon plans to list its biosimilars business by March 2026, targeting a double-digit market share in the U.S. with five new ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March ... of high-priced and complex biologics drugs used to treat illnesses such as cancer ...

HYDERABAD (Reuters) - Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by ... of high-priced and complex biologics drugs used to treat illnesses such as cancer ...

The report projects a 3.84% increase in pharmacy and an increase of 2.3% in non-pharmacy spend over that timeframe. The report also includes a comprehensive analysis of emerging trends and pricing ...

This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, ...